Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer drug start-up Peloton raises $18M

This article was originally published in Scrip

Executive Summary

Peloton Therapeutics, a Dallas, Texas-based early-stage small-molecule cancer drug company, has come out of stealth mode. It has announced that it raised $18 million in a series A financing for development on three in-licensed programmes from the University of Texas Southwestern Medical Center. This follows an $11 million grant from cancer research funds provided by the state of Texas.

You may also be interested in...



Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio

Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Early-stage venture capital funding continues to decline, but corporate VC dollars and other sources of cash are emerging to fund startups. Also, biopharma companies raised $436.3m in 15 recent financings.

ChemoCentryx cuts price to get $45M IPO away

ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).

Topics

Related Companies

UsernamePublicRestriction

Register

SC013893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel